The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).
 
Gunter Von Minckwitz
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Myriad Genetics (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Teva (Inst); Vifor Pharma (Inst)
 
Marion Jennifer Procter
Research Funding - Roche (Inst)
 
Evandro De Azambuja
Honoraria - Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
Research Funding - Roche/Genentech (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Roche/Genentech
 
Dimitrios Zardavas
Research Funding - AstraZeneca (Inst); Genentech (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Tesaro (Inst)
 
Adam Knott
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Giuseppe Viale
Consulting or Advisory Role - AstraZeneca; Dako; Roche/Genentech
Travel, Accommodations, Expenses - Celgene; Roche
 
Thomas M. Suter
No Relationships to Disclose
 
Amal Arahmani
Research Funding - AstraZeneca (Inst); Genentech (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Tesaro (Inst)
 
Nathalie Rouchet
No Relationships to Disclose
 
Emma Clark
Employment - Roche/Genentech
Patents, Royalties, Other Intellectual Property - Roche/Genentech
 
Mark Benyunes
Employment - Roche/Genentech
 
Istvan Lang
No Relationships to Disclose
 
Christelle Levy
Consulting or Advisory Role - AstraZeneca; Novartis; Roche
Travel, Accommodations, Expenses - Eisai; Pfizer; Roche
 
Denise A. Yardley
No Relationships to Disclose
 
Jose Bines
Consulting or Advisory Role - Abbvie; Genomic Health; Roche
Travel, Accommodations, Expenses - AstraZeneca
 
Richard D. Gelber
Research Funding - AstraZeneca (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Martine J. Piccart-Gebhart
Consulting or Advisory Role - AstraZeneca; Crescendo Biologics; Debiopharm Group; HUYA Bioscience International; Lilly; MSD; Novartis; Periphagen; Pfizer; PharmaMar; Radius Health; Roche/Genentech
Research Funding - AstraZeneca (Inst); Crescendo Bioscience (Inst); Debiopharm Group (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Periphagen (Inst); Pfizer (Inst); PharmaMar (Inst); Radius Health (Inst); Roche/Genentech (Inst)
 
Jose Baselga
Leadership - Infinity Pharmaceuticals; Varian Medical Systems
Stock and Other Ownership Interests - GRAIL; Infinity Pharmaceuticals; Juno Therapeutics; PMV Pharma; Varian Medical Systems
Consulting or Advisory Role - Eli Lilly, Novartis; GRAIL